Cargando…

Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and Treatment

Tyrosine kinase inhibitors (TKI) belong to a new class of molecular multitargeted anticancer therapy which targets different growth factor receptors and hence attenuates cancer cell survival and growth. Since their introduction as adjunct treatment for renal cell carcinoma and gastrointestinal strom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmadieh, Hala, Salti, Ibrahim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824811/ https://www.ncbi.nlm.nih.gov/pubmed/24282820 http://dx.doi.org/10.1155/2013/725410

Ejemplares similares

Tyrosine kinase inhibitors induced thyroid dysfunction: myth or reality?
por: Malhotra, Anjli, et al.
Publicado: (2023)

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
por: Kloth, J S L, et al.
Publicado: (2015)

Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma
por: Eroukhmanoff, Juliette, et al.
Publicado: (2016)

SUN-414 Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: An Experience from a Tertiary Care Hospital
por: Wangnoo, Subhash Kumar, et al.
Publicado: (2020)

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
por: Shyam Sunder, Sunitha, et al.
Publicado: (2023)

The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer
por: Poliaková, Michaela, et al.
Publicado: (2018)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
por: Saronni, Davide, et al.
Publicado: (2022)

Chaperone-mediated destruction of erbB2: relevance to tyrosine kinase inhibitors
por: Gee, Julia MW
Publicado: (2002)

Establishing the role of the FES tyrosine kinase in the pathogenesis, pathophysiology, and severity of sepsis and its outcomes
por: Laight, Brian J., et al.
Publicado: (2023)

Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management
por: Abdullah, Shaad E., et al.
Publicado: (2012)

Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: A retrospective study
por: Iwasaki, Hiroyuki, et al.
Publicado: (2019)

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
por: Alves, Raquel, et al.
Publicado: (2021)

Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology
por: Rozen, Esteban Javier, et al.
Publicado: (2021)

Controversies in the Management and Followup of Differentiated Thyroid Cancer: Beyond the Guidelines
por: Ahmadieh, Hala, et al.
Publicado: (2012)

Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
por: Schöffski, P, et al.
Publicado: (2010)

Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study
por: Escudero-Ortiz, Vanesa, et al.
Publicado: (2022)

Pathophysiology of Red Blood Cell Dysfunction in Diabetes and Its Complications
por: Williams, Alyssa, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Downregulation of miR-146a Contributes to Cardiac Dysfunction Induced by the Tyrosine Kinase Inhibitor Sunitinib
por: Shen, Li, et al.
Publicado: (2019)

Current understanding of tyrosine kinase BMX in inflammation and its inhibitors
por: Qiu, Le, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitor Induced Isolated Pericardial Effusion
por: Agrawal, Vineet, et al.
Publicado: (2015)

Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer
por: Pozo, Karine, et al.
Publicado: (2018)

Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis
por: Lechner, Kristina S., et al.
Publicado: (2020)

Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer
por: Ragusa, Francesca, et al.
Publicado: (2022)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
por: Novello, S, et al.
Publicado: (2010)

Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer
por: Rodríguez-Hernández, María A., et al.
Publicado: (2020)

Tyrosine Kinase Inhibitor–Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?
por: Ozgur Yurttas, Nurgul, et al.
Publicado: (2019)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

Mitochondrial and metabolic dysfunction in Friedreich ataxia: update on pathophysiological relevance and clinical interventions
por: Lynch, David R., et al.
Publicado: (2021)

Liver Pathophysiology—Its Relevance to Human Disease
Publicado: (1971)

Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects
por: Puliafito, Ivana, et al.
Publicado: (2022)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C., et al.
Publicado: (2020)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_atar1nh5r34ngji06l7l913ppr